📈 Markets & Finance
Live
This Stock Is Up 58% This Year. Is It too Late to Buy?
Written by Prosper Junior Bakiny for The Motley Fool -> One of Intellia Therapeutics' leading candidates recently aced a phase 3 study. This medicine's commercial opportunity is somewhat limited. …
Nasdaq News — 16 June 2026
Text:
15
0
0
One of Intellia Therapeutics' leading candidates recently aced a phase 3 study. The biotech could see strong returns, but there is ample risk to cons
Read Full Story at Nasdaq News →
Verified Source
WRDW News 12
The status of the stock market
Sources
📈 Markets & Finance
Sam Altman says OpenAI's top token spender uses 100 billion tokens a month — and they're not even the world leader
📈 Markets & Finance
Intel, AMD, Micron shares sink as Broadcom results spark semiconductor sector sell-off
📈 Markets & Finance
This Smart‑Money Legend Won Big on Intel. The Rest of His Portfolio Might Be Even More Revealing
📈 Markets & Finance
A new NJ bill would hand pet owners up to $900 in tax credits — and your state could be next
📈 Markets & Finance
Addressing Investor Transparency, Updates from Euronet Worldwide’s (EEFT) First Analyst Day in a Decade
📈 Markets & Finance
MGM Resorts stock jumps as Barry Diller's People Inc. makes bid to take over the company
